The company manufactures specialized multi-layer labels, cartons, and printed packaging materials primarily for the pharmaceutical and pesticide industries.
The company claims a niche in 'Fix-A-Form' multi-page labels, but financial metrics show a low net margin of 5% and negative EPS growth, suggesting a lack of pricing power or cost advantage. The average ROCE of 12.2% is barely above the cost of capital, indicating a weak competitive position.
Management has prioritized reinvestment in plant and machinery and maintaining high inventory levels over dividends. However, these investments have resulted in a significant decline in earnings per share over the period analyzed.
The business succumbed to a slow-motion liquidation as the niche 'Fix-A-Form' product became a commodity in a digital-first world. While revenue remained flat, the combination of rising input costs and a lack of pricing power squeezed the already thin 5% margins into net losses. Management continued to pour capital into unproductive machinery and bloated inventory, while the interest burden on their debt eventually overwhelmed the dwindling cash flow. The departure of the auditor was the early warning of a breakdown in internal controls that finally led to a total loss of investor confidence.
RichFakir rates Unick Fix-A-Form And Printers Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Unick Fix-A-Form And Printers Ltd is trading about 14% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Unick Fix-A-Form And Printers Ltd is: Not rated. A poor business at a fair price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Unick Fix-A-Form And Printers Ltd's fair value is about ₹53 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →